US biosimilars legislation could take some time to approve, meeting hears
This article was originally published in SRA
The new political environment in Washington, DC, is favourable towards biosimilars, but getting US biosimilars legislation approved is still likely to be a long haul. This was the message from Juliana Reed, director of the Office of Government Affairs at global pharma and medication delivery company Hospira, who spoke at a meeting on 23-24 April in London that was organised by the European Generic medicines Association.
You may also be interested in...
The UK government says it is on track to vaccinate the 15 million most vulnerable people by mid-February, and that a “major study” is under way to assess the potential impact of the new UK variant on vaccine efficacy.
Coronavirus Notebook: EU To Buy 30 Million Doses Of Valneva Vaccine, Russia To Issue Compulsory License For Remdesivir
The European Medicines Agency says hacked COVID-19 vaccine data has been leaked online, and Australia’s chief medical officer defends the Oxford/AstraZeneca vaccine against scientists’ claim that it is not effective enough.
A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.